Mutations of the Janus kinase 3 (JAK3) have been previously described to cause an autosomal recessive variant of severe combined immunodeficiency (SCID) usually characterized by the near absence of T and NK cells, but preserved numbers of B lymphocytes (T-B+SCID
Introduction
The Janus kinase 3 (JAK3) member of Janus kinases associates with the common ␥ chain (␥c) of the IL-2, 4, 7, 9, and 15 receptors and is necessary for normal downstream signaling by members of the signal transducer and activators of transcription (STAT) family. 1, 2 The central role of JAK3 in T cell development is highlighted by patients with JAK3-deficiency and severe combined immunodeficiency (SCID) due to the lack of circulating T cells and presence of dysfunctional B cells (T-B+ SCID). [3] [4] [5] Targeted disruption of the Jak3 gene in mice also leads to profound immunodeficiency, but with defects in both T and B cell development. [6] [7] [8] The T cell defect of JAK3-deficient humans and mice resembles that of IL-7 and IL-7 receptor ␣ chain (IL7R␣) null mice and IL-7R␣ deficient SCID patients, suggesting that defective IL-7 signaling largely accounts for the lack of thymocyte development in mice and humans lacking JAK3. [9] [10] [11] Additionally, JAK3-deficient humans and mice present with impaired NK cell development that is most likely due to defective IL-15 signaling, as IL-15 knockout mice have a nearly complete absence of peripheral NK cells. 12 We hypothesized that the phenotype of patients with partial JAK3 deficiency might be quite different from that of patients reported thus far with classical T-B+ SCID. Partial signaling through the IL-7 receptor in this case might be sufficient to sustain thymic development of T lymphocytes and to allow their appearance in the peripheral circulation where they could manifest consequences of defective signaling in other JAK3-dependent pathways. In this regard it is worth noting that mice with targeted disruptions of IL-2 or its receptor ␣ or ␤ chains are characterized by autoimmunity and/or lymphoproliferation, despite the well-established role of IL-2 in cellular proliferation. [13] [14] [15] This is thought to be a consequence of the lack of IL-2-mediated apoptotic signals for activated T lymphocytes. Depending on the context, therefore, IL-2 can have seemingly opposing effects. Although poorly defined, a role for JAK3 in mediating IL-2-dependent apoptosis signals is suggested by the presence of activated/memory and auto-reactive T cells in JAK3-deficient mice 16, 17 and the development of activated T lymphocytes in one patient with JAK3 deficiency. 18 These T cells also are characterized by a limited T cell receptor repertoire, consistent with oligoclonal peripheral expansion of the few thymocytes that escape the developmental blockade. 17, 18 We have been screening patients whose immunodeficiency status could be due to partial JAK3 deficiency and, in this report, we describe a family carrying mutations leading to severely reduced levels of functional JAK3, but allowing residual cytokine signaling and the development of peripheral T cells. Two siblings in this family had variable clinical presentations ranging from overt to very mild immunodeficiency, despite carrying identical JAK3 mutated alleles. These patients had elevated numbers of activated peripheral lymphocytes, and severe and progressive multi-organ lymphocytic infiltration was observed in one case. Studies of FasL expression in lymphocytes from one of these patients showed defective upregulation in response to IL-2 that could help explain these findings.
Results

Clinical history of patients
Four children resulted from the non-consanguineous union of two northern European parents. No biological samples were available from the first male child ( Figure  1 , subject II,1) who died at 10 months of age from Pneumocystis carinii pneumonia (PCP).
The medical history of subject II,2 included an undefined lung infection at age 1, a severe varicella infection and occasional ear and urinary tract infections until age 7. During laboratory evaluations as potential bone marrow donor for her brother (II,4) she was found to have reduced T cell counts and was subsequently maintained on antibiotic prophylaxis. At age 9, she developed recurrent cutaneous warts that spontaneously disappeared by age 14. At the time of this study she was 18 years of age and in good health.
The second male/fourth child (II,4) had delayed umbilicus healing and developed PCP at the age of 6 months. At age 2 he developed giardiasis and, at age 3, presented with pneumococcal pneumonia and a second PCP. At age 5, he developed severe varicella and, at age 7, a recurrent Giardia lamblia infection accompanied by hepatosplenomegaly and ascites. Lymphocytic infil- Figure 1 Family tree of study family. Four offspring were the result of this non-consanguineous union (*genotype analysis not performed). Pt II,1 died of PCP.
Genes and Immunity tration of the gut, bone marrow (Figure 2a) , and liver (Figure 2b ) was demonstrated which was characterized by a predominance of oligoclonal CD8 + T cells (data not shown). Attempts to treat the patient's condition with azathioprine and steroids were unsatisfactory, ultimately leading to treatment with allogeneic bone marrow transplantation (BMT) from his HLA-identical sister (II,3) at age 9. Although engraftment was demonstrated, the patient died from multi-organ failure complicating a sepsis episode 5 weeks after BMT. Pre-treatment DNA and EBV-B cells were available for analysis.
Immunological findings
The immunological phenotype of patient II,2 on admittance to the Clinical Center, NIH is reported in Table 1 together with that of her brother (II,4) at 6 months, 4 and 7 years of age. Both patients II,2 and II,4 demonstrated T cell lymphopenia primarily due to a reduced number of CD4 + T cells. In patient II,2, both CD4 + and CD8 + T subsets showed a large reduction in the number of naïve cells, identified by dual expression of CD45RA and CD62L, a finding consistent with reduced thymic output. In addition, patient II,2 had a high proportion of ␥␦ T cells in her peripheral blood, all of which were of the V␦2 subset. This finding was consistent with peripheral expansion of these cells, which can develop via extrathymic pathways. 19 Such an expansion was not apparent in patient II,4. One characteristic of T cells in both patients was the high percentage of T cells that expressed HLA-DR, indicating increased activation compared to normal controls. In addition, the NK cell counts in both patients were extremely low, whereas both B cell numbers were within the normal range or elevated ( Table 1) . The level of serum immunoglobulin (Ig) in patient II,4 at the time of his first hospitalization for PCP indicated a reduced production of IgG levels (IgG: 290 mg/dl, IgA: 27 mg/dl, IgM: 147 mg/dl) for which he was started on monthly infusions of intravenous immunoglobulin (IVIG). Serum Ig levels in patient II,2 were consistently normal. No other relatives in the family were known to have immunological problems.
Since proliferation studies performed in 1988 on samples from patient II,4 revealed defective T cell proliferation in response to PHA (Stimulation Index = 7.7, not shown), we proceeded to determine whether this was the case for the patient II,2 as well. Lymphocytes from this patient failed to properly proliferate in response to PHA and ConA, as well as Candida, tetanus toxoid, and diphtheria toxoid. However, these lymphocytes did proliferate in response to direct stimulation through the TcR, and this proliferation was greatly augmented by IL-2 stimulation and normalized in a 7-day proliferation assay ( Table 2) .
Analysis of IL-2R signaling
In the attempt to characterize defects of cytokine signaling in the patient's cells, we evaluated whether JAK3 was activated and tranduced signals in a normal manner in response to IL-2. As shown in the upper panel of Figure 3a , JAK3 was phosphorylated in response to IL-2 stimulation in PHA-activated peripheral blood mononuclear cells from the parents (subjects I,1 and I,2) of the affected children. In contrast, patient II,2 had an extremely low response, consistent with the very low detectable levels of JAK3 protein in the immunoprecipit- 
Analysis of JAK3 sequence in cDNA and genomic DNA samples
The findings of abnormal JAK3 expression and function in patient II,2 led us to assess whether mutations existed in the JAK3 gene of this family. Initially, cDNA was analyzed from PHA-activated PBMC from the patient. As seen in the left panel of Figure 4a , a doublet was evident in the PCR product generated following amplification of the region spanning nucleotides 1961-2996. Sequence analysis revealed that the lower band contained the normally spliced exon 18 sequence, while the upper band resulted from defective splicing between exons 18 and 19. This abnormal cDNA included a 87-bp segment of intronic sequence, resulting in a predicted premature stop 6 amino acids following the missed splice site at the intron 18 splice donor sequence. This splicing abnormality was not observed in PCR products using cDNA from healthy controls as a template ( Figure 4a , right panel). Sequence analysis of the RT-PCR product and the genomic DNA corresponding to this region revealed a 2775 (+3) G to C mutation in the consensus sequence of the intron 18 splice donor site in both patients II,2 and II,4 ( Figure 4b ). Maternal inheritance of this allele was indicated, as this mutation was present in genomic DNA The results are the mean ± s.d. obtained from proliferation assays performed in triplicate. from the mother (Figure 4b ). To rule out the possibility that this nucleotide change was a polymorphism, we screened normal European donors for the presence of this mutation by an HphI restriction digest assay. The mutant restriction pattern was not detected in 100 normal chromosomes screened by this method (data not shown). Additionally, genomic sequencing analysis led to the discovery of a paternally-inherited mutation in the translation initiation codon of JAK3 (96A to G). This mutation was present in the father (subject I,1) and patient II,2 and II,4 ( Figure 4b ).
Analysis of JAK3 protein and signaling function in B cell lines
In an effort to confirm our findings in primary cells and better analyze the JAK3 mutant protein in terms of expression and function, EBV-transformed B cell lines were prepared from patient II,2 and her father, subject I,1. Additionally, several experiments were performed on EBV-transformed B cell lines from patient II,4 before the cell line was permanently lost due to an equipment mal- In addition, the father (I,1), daughter (II,2), and son (II,4) expressed a smaller molecular weight protein that was immunoprecipitated by the C-terminal anti-JAK3 antibody. This smaller protein was not present in the control EBV-B cell line. In the case of patient II,4, this truncated protein was only detectable during anti-phosphotyrosine blotting, likely due to the increased sensitivity of this assay (Figure 5a , upper right panel). In the case of the father (I,1) and the daughter (II,2), this truncated protein was also readily detectable following immunoprecipitation or direct Western analysis with the C-terminal anti-JAK3 (Figure 5a and 5b, upper panels). Since this smaller protein was not detected with an N-terminal anti-JAK3 (not shown), these findings were consistent with the paternally inherited mutation in the JAK3 initiation start site. An alternative translation initiation at a downstream methionine likely accounted for the production of the observed N-terminally truncated JAK3 protein. Interestingly, this smaller JAK3 protein showed no difference in its level of tyrosine phosphorylation following IL-2 treatment, suggesting that it failed to propagate IL-2-dependent signals (Figure 5a , upper left and right panels). As previously mentioned, the maternally inherited mutations would be predicted to result in a Cterminally truncated protein. However, no evidence was found for expression of maternally inherited JAK3 allele in either sibling (II,2 or II,4) using an N-terminal anti-JAK3 antibody (not shown).
Next we examined STAT5A phosphorylation in response to IL-2 stimulation in these cell lines. STAT5A phosphorylation was low in patient II,2 and absent in patient II,4 compared to the normal control or their father (I,1), although the expression levels of STAT5A were normal ( Figure 5c , upper and lower panels). Thus, the levels of STAT5A phosphorylation correlated well with the level of normal-sized, functional JAK3 present in these cell lines.
TcR V␤ usage
We next proceeded to characterize the phenotype of the T lymphocytes that developed in the surviving affected child despite the severe reduction in functional JAK3 pro- . Genomic DNA from the indicated family members was sequenced from exon 1 (reverse strand is shown, left panels) and exon/intron 18 (right panels). Published cDNA sequence (accession number U09607) was used as a reference for base numbering. Mutations are indicated by the arrow (b). (c). Genomic PCR products generated from subjects heterozygous for the maternally inherited mutation had both cut (259 and 104 base pair fragments) and uncut DNA (363 base pair fragment) following HPHI digestion, whereas PCR products from unaffected controls (NL) were completely digested (M: marker).
tein. Analysis of the TcR V␤ repertoire in patient II,2 demonstrated that all V␤ families were transcribed by her peripheral blood T lymphocytes. The over-representation of some V␤ families (eg, V␤8), however, suggested preferential expansion of oligoclonal T cell populations (Figure 6a) . Additionally, heteroduplex analysis of the V␤ segments amplified from a healthy control generated a smear pattern indicative of highly heterogeneous molecular species, 20 whereas discrete bands super-imposed on a smear pattern were visible in most of the V␤ families analyzed in patient II,2. Taken together, these data suggest that patient II,2 had a polyclonal T cell repertoire with evidence of oligoclonal expansion (Figure 6a, inset) . This possibility was confirmed by sequence analysis of TcR V␤8 and V␤9 clones from patient II,2 that showed a biased utilization of TcR V␤ junctional regions (Table 3) .
Defective upregulation of Fas ligand in IL-2-stimulated patient cells
The presence of significant numbers of peripheral T cells with an activated phenotype (patients II,2 and II,4) and the development of a multi-organ lymphocytic infiltration in patient II,4, were notable features in this kindred affected with JAK3 deficiency. Given the results of a recent report showing that restoration of normal activation-induced cell death (AICD) in T lymphocytes from Il-2R␤ knockout mice occurred only in association with functional STAT5 signaling, 21 we hypothesized that IL-2-dependent upregulation of pro-apoptotic molecules might be JAK3-dependent. One critical pro-apoptotic pathway regulated by IL-2 is Fas/FasL, abrogation of which results in lymphoproliferative disease and autoimmunity in humans. 22 Western blot. analysis of FasL expression in normal PBMCs showed low levels of FasL in unstimulated conditions, but greatly increased expression following 24 h of stimulation with IL-2. In contrast, neither unstimulated nor IL-2-treated PBMCs from patient II,2 expressed detectable levels of FasL, indicating that this pathway of upregulation was defective in these cells expressing extremely low levels of functional JAK3 (Figure 6b ).
Discussion
The requirement for JAK3 in thymic development is clearly evident in patients with absolute deficiency in JAK3 function, who have nearly undetectable peripheral T cells. [3] [4] [5] This phenotype is paralleled in Jak3 knockout mice which show a profound reduction of early thymic progenitor cells. [6] [7] [8] 17 Taken together, the phenotype of complete JAK3 deficiency in humans and mice establishes the importance of JAK3 in the maturation of T cells. Most of the patients described in previous studies lacked detectable JAK3 activity, preventing peripheral T cell development, and prohibiting examination of the role of JAK3 in the function of peripheral T lymphocytes.
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The JAK3-deficient patients described here are compound heterozygotes carrying two previously undescribed JAK3 mutations, whose phenotypes indicate a broader spectrum of disease than previously recognized. Affected individuals in this family express a very small amount of functional JAK3 protein, while having mutations in both alleles of JAK3. This is likely due to occasional correct recognition of the intron 18 splice donor site in the maternal allele despite the mutation in the consensus sequence. The truncated protein that results from the paternal allele, in contrast, is predictably non-functional as the N-terminus has been shown previously to be required for association with ␥c. 24, 25 Patient II,4 carried the identical mutations as patient II,2, yet no expression of functional JAK3 was detected in B cell lines generated from this patient. However, the presence of peripheral T cells in this patient does suggest that low level JAK3 expression had occurred at least some time during T cell development. Whether a difference in JAK3 expression levels between the siblings resulted in differences in disease severity is unknown, but it is an intriguing possibility. Low and variable levels of JAK3 expression could account for the unique features of affected individuals in this family: T cell counts in the low range, mild immunodeficiency with increased but not overwhelming susceptibility to infections, and the persistence of activated T cells. Interestingly, NK cell counts were low in both patients II,2 and II,4, suggesting that NK cell development is more dependent on JAK3 signaling than is T cell development.
It must be noted that spontaneous reversion of genetic defects in lymphocytes has been demonstrated to be the basis of the unexpectedly mild immunological phenotypes in ADA deficiency and X-linked-SCID patients. 26, 27 The occurrence of genetic reversions in patients II,2 and II,4 therefore could have potentially explained their atypical immune phenotypes and the development of peripheral T lymphocytes. Although we have not formally ruled out the presence of genetic revertants in these patients, it is unlikely that such rare events would arise in two members of the same family. In addition, revertant T lymphocytes would be expected to have a strong selective advantage and to express JAK3 to levels comparable to the heterozygous parents. On the contrary, only barely detectable levels of JAK3 could be immunoprecipitated from PBMCs from patient II,2 (Figure 3a) , indicating an overall deficiency in JAK3. We therefore conclude that most, if not all, T lymphocytes present in peripheral blood from patient II,2 have developed despite their extremely low levels of JAK3 expression. This would not be entirely unexpected, as patients with attenuated ␥c deficiency develop T cells as well. [28] [29] [30] Despite being in substantial numbers, the T cells that develop in patients from this family are abnormal in some respects. For example, the T cells that are present in the periphery of patient II,2 have a skewed T cell repertoire. This finding is consistent with peripheral oligoclonal expansion, similar to that observed in Jak3 −/− mice. 16, 17, [31] [32] [33] [34] In addition, the finding of elevated ␥/␦ T cells indicates a reduced thymic output in this patient.
One conclusion that can be made from identification of JAK3 mutations in these patients is that the phenotype of JAK3 deficiency is more heterogeneous than previously recognized, ranging from the clinical presentation of SCID [3] [4] [5] 23 to mild immunodeficiency (patient II,2). The developmental effects of JAK3 deficiency vary from the virtual absence of circulating T cells [3] [4] [5] 23 to the development of substantial numbers of peripheral T lymphocytes (Table 1 and Brugnoni et al   18   ) , which may even lead to lymphoproliferative syndromes as in patient II,4 ( Figure 2 ). This variation occurs even among patients with identical JAK3 mutations, as is evident in the kindred that we describe here. Because of his early death from PCP, it is tempting to speculate that patient II,1 was also carrying the JAK3 mutations found in the other members of the family. If this very likely possibility were true, the clinical heterogeneity allowed by JAK3 mutations within this family would be even greater than what we currently appreciate. We do not know the explanation for this clinical heterogeneity, but speculate that other genetic factors outside of JAK3 mutations may play a role in the disease phenotype. 35 Another very surprising finding in this study was that despite the presence of minimal amounts of JAK3, patient T cells proliferated in response to IL-2 stimulation. Moreover, the addition of T cell receptor stimulation to IL-2 treated cultures apparently normalized proliferation of patient cells by 7 days following stimulation (Table 2) . Whether decreased IL-2-induced apoptosis plays a role in this normalization is unknown, but possible. Furthermore, IL-2-dependent proliferation occurred despite the fact that IL-2-dependent STAT5 phosphorylation was strikingly low. Perhaps activated PBMC produce factors that complement the JAK3 defect in a manner similar to the correcting effect of IL-3 in Jak3-deficient mice. 36 Despite the data indicating the importance of STAT5 in IL-2-and JAK3-dependent lymphocyte proliferation, 37 it appears that only a small amount of activation of this signal transduction pathway is required to effect this function. Thus, once T cells progress through thymic maturation even very low levels of functional JAK3 can sustain their proliferation upon activation.
Additionally, the finding that the patients' cells proliferate in response to IL-2 in a relatively normal manner, especially with concomitant T cell receptor engagement, has important implications. It is well known that IL-2 receptor signal transduction pathways lead to apoptosis as well as proliferation. 38 Indeed the pro-apoptotic role of IL-2 may supercede its proliferative role in some settings, as demonstrated in IL-2 and IL-2 receptor deficient mice and humans, whose phenotype is characterized by lymphoproliferation and autoimmunity. [13] [14] [15] 39 In our experiments, JAK3-deficient patients' T cells did not upregulate FasL in response to IL-2 suggesting that this process is entirely JAK3-dependent. We speculate that the inability to upregulate this key pro-apoptotic signal may explain the persistence of activated lymphocytes and a general predisposition to uncontrolled proliferation that may have been the basis of the lymphoproliferative syndrome observed in patient II,4. Our data suggest that there may exist different thresholds for IL-2-induced survival and apoptosis. Clearly we are limited in our ability to establish the ramifications of defective IL-2 induced FasL upregulation by studying the single living affected patient from this kindred; further studies in patients with JAK3 mutations with similar effects and/or the establishment of appropriate cellular or animal models will be informative in this regard.
JAK3 deficiency is being evaluated as a candidate disease for gene therapy. 40, 41 Our findings suggest that the achievement of low levels of JAK3 expression through gene transfer may successfully induce T cell development and therefore support the development of gene therapy applications for this disease. On the other hand, a degree of caution comes from the observed lymphocytic infiltration syndrome in patient II,4, which may have resulted from failure of T cell homeostasis maintenance mediated by sub-optimal levels of JAK3 expression. In vitro and/or in vivo experiments of human T lymphocyte development following gene transfer into JAK3-deficient hematopoietic progenitors may be necessary to gain more information on the levels of JAK3 expression that can be achieved in peripheral T cells of subjects who undergo gene transfer-based treatments.
The identification of JAK3 mutations in this family expands our understanding of the clinical presentation of genetic defects in JAK3, as it establishes that JAK3 deficiency may be present in patients with mild immunodeficiencies and relatively normal peripheral T cell counts. Not surprisingly, however, JAK3-deficient T cells are not fully normal. Interestingly, they lack normal regulation of FasL, likely explaining the persistence of activated peripheral T cells in affected patients. Taken together these data have important implications for the evaluation of primary immunodeficiencies, as well as establish a new role for JAK3 in IL-2-mediated T cell homeostasis in humans.
Patients and methods
Subjects
The subjects described in this study provided written, informed consent for participation in National Institute of Arthritis and Musculoskeletal and Skin Diseases Protocol 99-AR-0004. Following a medical interview and physical examination, the patients' peripheral blood mononuclear cells (PBMC) were harvested by phlebotomy or automated apheresis using standard protocols.
Cell purifications and culture
Both heparinized whole blood and crude apheresis product underwent Ficoll gradient separation to obtain purified PBMC that were enumerated and used fresh or cryopreserved. PBMC and lymphoblastoid B cell lines obtained by immortalization with Epstein-Barr virus (EBV) were cultured in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS), 2 mM L-glutamine (all from Life Technologies, Grand Island, NY, USA), penicillin (100 U/ml), streptomycin (1 mg/ml), and fungizone (0.25 g/ml, Biofluids, Rockville, MD, USA).
Lymphocyte immunophenotyping
Anticoagulated (EDTA) fresh peripheral blood samples were stained using the whole blood lysis method and analyzed by flow cytometry (Becton Dickinson), as previously described. 42 Lymphocyte subpopulations were identified with directly conjugated mouse anti-human monoclonal antibodies (Mabs) specific for the following: CD2, CD3, CD4, CD8, TcR␣/␤, CD16/56, CD45RO, CD28, CD57, CD62L, HLA-DR (Becton Dickinson), TcR␥/␦ (Endogen, Woburn, MA, USA), CD45RA (Beckman Coulter/Immunotech, Brea, CA, USA), CD19, and CD20 (Becton Dickinson). NK cells were identified by a combination of anti-CD16 and anti-CD56 (Becton Dickinson), evaluated on CD3-negative lymphocytes. Peripheral blood lymphocyte counts were obtained in parallel using a Coulter Counter (Coulter Corporation, Maine, FL, USA).
T cell proliferation assays PBMC (2 × 10 5 per well) were plated in triplicate in RPMI 1640 medium (Life Technologies) supplemented with 5% human serum, 4 mM L-glutamine, 1% non-essential amino acids, 1 mM Na pyruvate, and 50 g/ml gentamicin (LifeTechnologies) with or without the following stimulants: phytohaemoagglutinin (PHA, 10 g/ml, Difco), concavalin-A, (Con-A, 25 g/ml, Sigma, St Louis, MO, USA), OKT3 (100 ng/ml, Ortho Biotech), IL-2 (100 U/ml, Roche), pokeweed mitogen (PWM, 1:400, Life Technologies), tetanus toxoid (3 LF/ml, Connaught Laboratories, LTD, Toronto, Canada), or Candida albicans (1:30, Hollister Stier Labs, LLC, Spokane, WA, USA). Cultures were incubated at 37°C, 5% CO 2 for 3 days (PHA, Con-A, OKT3, IL-2, OKT3+IL-2) or 7 days (PWM, tetanus, candida) and then pulsed with 1 Ci per well of 3 H-thymidine during the last 6 h of culture. Cells were then harvested, and incorporated radioactivity was determined with a scintillation counter (Wallac, Uppsula, Sweden).
TcR V␤ family analysis
Total RNA was isolated from 3-5 × 10 6 PBMC using the PureScript RNA Isolation Kit (Gentra Systems). First strand cDNA was prepared from 5 g of RNA using the SuperScript Preamplification System (Gibco-BRL) and amplified using an oligonucleotide primer specific for the TcR constant ␤ region (C␤) coupled to a second primer specific for each of 24 different TcR variable ␤ (V␤) families. Oligonucleotide sequences for these reactions have been previously published. 43 PCR products were subjected to electrophoretic separation in 2% agarose and visualized by exposure to UV light. The intensity of each band was quantified using the NIH Image software (http://rsb.info.nih.gov/nih-image). The relative percentage of expression of each TcR V␤ was calculated by normalizing the intensity of individual families to the sum of the intensity values of all TcR V␤ segments. 30 For heteroduplex analysis, 20 l of the TcR V␤ PCR reactions was heated at 95°C for 5 min and cooled to 50°C for 1 h before being separated using nondenaturating polyacrilamide gel electrophoresis and visualization by UV transillumination. For analysis of the junctional amino acid sequences of selected TcR V␤ families, TcR V␤ PCR products were inserted into the pCR 4-TOPO plasmid using the TOPO TA Cloning kit (both from Invitrogen, Carlsbad, CA, USA) and sequenced using the T3 primer on an ABI 373 automated sequencer sequencer (PE applied Biosystems, Foster City, CA, USA).
Immunoprecipitation and Western blotting
After 4 h of culture in 2% FCS (for PBMC) or in the absence of fetal calf serum (FCS) (for EBV-transformed B cells), 5-10 × 10 7 cells were resuspended in 1 ml of RPMI 1640 medium and stimulated at 37°C with IL-2 (1000 IU) for 15 min. Following stimulation, lysis in a Triton-X buffer, immunoprecipitation, PAGE, and immunoblotting were performed as described previously. 44 Briefly, lysates were immunoprecipitated with anti-JAK3 (␣-JAK3) 45 or anti-STAT5a (␣-STAT5a) 46 rabbit polyclonal antibodies and immunoblotted with anti-phosphotyrosine mouse monoclonal Ab (␣-PY, 4G10, Upstate Biotechnology, Lake Placid, NY, USA) and with the original immunoprecipitation antibody as described. 44 Detection of immunocomplexes was then performed by enhanced chemiluminescence (ECL, Amersham Life Science, Arlington Heights, IL, USA). For direct Western blot analysis of cell lysates, 100 g of protein was subjected to PAGE and immunoblotted using the ␣-JAK3 or ␣-STAT5 antibodies as described.
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Sequence analysis RNA was prepared from 2 × 10 6 PBMC stimulated with PHA for 24 h using RNA STAT-60 kit (Tel-Test Incorporated, Friendswood, TX, USA). Subsequently, cDNA was prepared from the RNA template using a first-strand cDNA kit (Boehringer Mannheim, Indianapolis, IN, USA). Overlapping regions of the JAK3 coding regions were PCR-amplified from this cDNA using the following primers: Amplification products were ligated into a TA cloning vector (Invitrogen) and sequenced using M13 forward and reverse primers on an ABI 377 sequencer (PE Applied Biosystems).
Genomic DNA was obtained using the Wizard DNA purification kit (Promega, Madison, WI, USA), and sequencing of the entire coding sequence of the JAK3 gene was performed. To confirm mutations revealed by cDNA analysis, as well as to obtain sequence information at the 5Ј proximal region of the coding sequence 100 ng of genomic DNA template was used to amplify exons and flanking intronic sequence using the following M13-tailed primers:
JAK3 exon 1 forward: TGTAAAACGACGGCCAGTCC TCCAGCACTCCTTTCCATG, JAK3 exon 1 reverse: AGGAAACAGCTATGACCATG ACTTCTGCAGGCAACTATTCC, JAK3 exon 18 forward: TGTAAAACGACGGCC AGTGCATCCAGGTGCCTGGACATC, JAK3 exon 18 reverse: AGGAAACAGCTATGACCAT ACGTTCCCAGCCTACCTAAAG.
PCR products were directly sequenced using M13 primers (Amersham, Piscataway, NJ, USA) on an ABI 377 sequencer.
PCR-based mutational analysis screening
The JAK3 mutation present in intron 18 ablated an HphI restriction site. JAK3 exon 18 forward and reverse primers were used to amplify exon 18 and surrounding intronic sequences from family members and 50 healthy controls. PCR products were digested overnight at 37°C with HphI (New England Biolabs, Beverly, MA, USA) and analyzed by gel electrophoresis.
Histopathology
Microtome sections (3-4 m-thick) were obtained from paraffin-embedded bone marrow and percutaneous liver biopsy samples and stained with hematoxylin and eosin for morphological examination. Slides were examined using an Olympus BX41 microscope and photographed at magnification of ×400 and ×600 using an Olympus DP11 digital camera.
Analysis of Fas ligand expression
Isolated PBMC were incubated with or without IL-2 (1000 U/ml) for 24 h. Protein lysates were electrophor-esed on a 12.5% PAGE gel. Western blotting was performed as previously described 44 using an IgG1 monoclonal anti-human FasL (G247-4, Pharmingen, San Diego, CA, USA) at a dilution of 1:1000.
